Regulatory
March 2026
FDA compounded semaglutide shortage status: what changes in 2026
The FDA's removal of semaglutide from the drug shortage list in late 2024 triggered enforcement deadlines for compounding pharmacies in April–May 2025. We track what this means for telehealth providers and what patients sourcing compounded GLP-1s need to know in 2026.
Regulatory
February 2026
Research peptides and the FDA grey market: what's legal in 2026
Research peptides occupy a complex regulatory position. They are not FDA-approved drugs, not controlled substances, and not legal for human consumption — yet they are sold openly online. We explain the current legal framework, why enforcement is uneven, and what buyers should understand.
Regulatory
January 2026
BPC-157 regulatory risk: what happened in Canada and what it means for US buyers
Health Canada's action against Canlab Sciences and the Supreme Court of Quebec enforcement order in early 2026 sent ripples through the research peptide community. We examine what happened and what cross-border regulatory risk looks like for US-based researchers.
Vendor news
March 2026
Peptide Sciences shutdown: what researchers need to know
Peptide Sciences — a long-standing and widely cited vendor — appears to have ceased operations in early 2026. We confirm the shutdown, explain what to watch for with auto-renewals, and recommend verified alternatives with equivalent or superior COA documentation.
Vendor news
February 2026
Science.bio closes January 2026 — affected compounds and where to source them
Science.bio ceased operations in January 2026. We track which compounds were most affected, which vendors have absorbed their catalog, and provide updated sourcing recommendations for researchers who relied on Science.bio as a primary source.
Research
March 2026
How to read a peptide COA: HPLC, mass spec, and endotoxin testing explained
A Certificate of Analysis is only as useful as your ability to interpret it. We walk through HPLC chromatograms, mass spectrometry identity confirmation, lot number traceability, endotoxin (LAL) results, and the difference between third-party and in-house testing — with a practical pre-purchase checklist.
Research
March 2026
Retatrutide Phase 2 data review: what the trial results show
Retatrutide (LY3437943) demonstrated greater metabolic endpoints than single and dual agonists in Phase 2 trials. We break down the published data, explain the triple-receptor mechanism in plain language, and examine what this means for researchers sourcing the compound.
Research
January 2026
How to read a peptide COA: HPLC, mass spec, and endotoxin testing explained
A Certificate of Analysis is only as useful as your ability to interpret it. We walk through each component of a proper research peptide COA — HPLC chromatograms, mass spectrometry data, lot number traceability, and endotoxin (LAL) results — with annotated examples.
✍
More articles coming soon
We publish regulatory updates, vendor news, and research analysis regularly. Subscribe in the sidebar to get notified when new articles are posted.